Introduction {#sec1-1}
============

Enteric fever remains an important public health challenge for the developing world. Geographically, south central and southeast Asia have the highest incidence of typhoid fever with an estimated 100 cases per 100,000 person-year.\[[@ref1]\] Risk factors commonly associated with a high incidence of typhoid fever include poor sanitation, limited access to clean drinking water and low socioeconomic status.\[[@ref2]\] Changing susceptibility patterns of typhoidal *Salmonella* spp. has also added to the challenges faced by the treating physician. While multidrug-resistant *Salmonella* spp. has become a thing of the past in the Indian subcontinent, fluoroquinolone-resistant *Salmonellae* spp. have emerged as a formidable problem.\[[@ref3][@ref4]\] Consequently, intravenous ceftriaxone and oral azithromycin are increasingly being used in the empirical treatment of typhoid fever.\[[@ref5]\] Although ceftriaxone continues to be effective against *Salmonella* spp., it is parenteral administration, cost and longer time for defervescence are factors that limit its use as an ideal antibiotic for enteric fever.\[[@ref4]\]

Azithromycin has been shown to be equally effective, or in some cases, a superior treatment alternative to chloramphenicol or fluoroquinolones by several randomized control trials.\[[@ref6][@ref7]\] It has the ability to achieve intracellular concentrations which are 50--100 times higher than the serum level of the antibiotic.\[[@ref7]\]

Guidelines for testing azithromycin susceptibility for *Salmonella* Typhi were released by Clinical and Laboratory Standards Institute (CLSI) in 2015.\[[@ref8]\] EUCAST does not prescribe any clinical breakpoints for azithromycin testing but mentions that azithromycin has been used in the treatment of S. Typhi infections with minimum inhibitory concentration (MIC) ≤16 mg/L.\[[@ref9]\] The emergence of azithromycin resistance in *Salmonellae* spp. has been documented by several studies.\[[@ref10]\]

We investigated the antibiotic susceptibility pattern of azithromycin in *Salmonella* spp. isolates from a tertiary care hospital to detect emerging resistance and change in MICs over a 5-year period. The study also assessed the reliability of disc diffusion as a screening test to detect azithromycin resistance by comparing it with the MICs of the drug.

Materials and Methods {#sec1-2}
=====================

Bacterial strains {#sec2-1}
-----------------

The study was conducted in a 1200 bed tertiary care hospital in Southern India between January 2013 and December 2017. A total of 100 *Salmonella enterica* strains recovered from blood samples were included in the study. Isolates were identified by standard biochemical reactions and VITEK 2 compact system (bioMérieux). The confirmation of identification was done by agglutination with specific antisera (Denka Seiken).

Azithromycin susceptibility testing {#sec2-2}
-----------------------------------

Antibiotic susceptibility testing was performed by Kirby Bauer disc diffusion method using azithromycin discs (15 μg). Azithromycin discs from two different manufacturers were used for disc diffusion (HiMedia and BD BBL sensi disc). Testing was done in triplicate for each isolate and disc. Disc diffusion diameters were recorded as mean of three readings. MIC of azithromycin was determined using Etest (bioMérieux). CLSI (2015--2017) guidelines were used to interpret azithromycin susceptibility-sensitive ≥13 mm and ≤16 mg/L and resistant ≤12 mm and ≥32 mg/L. Since CLSI mentions azithromycin breakpoints for *S*. Typhi only, these were used for interpreting *Salmonella* Paratyphi A and Group B *Salmonella* spp. susceptibility also. MIC50 and MIC90 of the isolates were determined. *Escherichia coli* ATCC 25922 and *Staphylococcus aureus* ATCC 25923 were used as the control strain for all susceptibility testing.

Errors in susceptibility were defined as follows:

Very major error: False susceptible result by disc diffusion compared to the MIC valueMajor error: False resistant result produced by disc diffusion compared to MIC valueMinor errors: A difference of \>2 mm in disc diffusion diameters while using two different discs.

Synergy testing {#sec2-3}
---------------

The evaluation of 10 strains of *Salmonella* Typhi for *in vitro* synergy between azithromycin and ceftriaxone was performed. Mueller-Hinton agar plates were inoculated with the suspension of the study strains grown to an optical density of 0.5 McFarland units. For each isolate, MIC of azithromycin and ceftriaxone was determined individually and in combination (AB Biodisk Etest Customer Information Sheet EAS023). For combination testing, E strip A (azithromycin) was put on the inoculated MHA plate and left for 1 h at room temperature. After an hour, this strip was removed after marking its outline, was washed with alcohol and stored as MIC reading scale. E strip B (ceftriaxone) was placed on the imprint of E strip A immediately and incubated at 35°C for 18 h. MIC scales were used to read the combination MIC gradients.

Fractional inhibitory concentration index (FIC index) calculations were made according to the formula:

FIC index = MIC~AB~/MIC~A~ + MIC~BA~/MIC~B~

Synergy was defined as MIC of combination ≥2 dilutions lower than MIC of the most active drug alone or FIC index ≤0.5.

Polymerase chain reaction {#sec2-4}
-------------------------

Mechanism responsible for azithromycin resistance was studied by amplifying *mphA*, *mphB*, and *mefB* gene using previously published primers.\[[@ref11]\] The thermal method of DNA extraction from *Salmonellae* spp., described by Gibson and McKee, was used with minor modifications.\[[@ref12]\] Briefly, isolates were grown on brain heart infusion agar plates for 18--24 h. 2--3 colonies were scooped using an inoculation loop and suspended in 100 μl of sterile distilled water. The suspension was heated in a dry bath at 95°C for 15 min. After centrifugation the 1 μl of supernatant solution was used as DNA template for polymerase chain reaction (PCR).

PCR reactions were done in 25 μl volumes using EmeraldAmp^®^ MAX PCR Master Mix, 100 ng of each primer and the extracted whole DNA as the template. The PCR was carried out in Primus 25 thermal cycler (Peqlab) starting with an initial denaturation at 95°C for 3 min. This was followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s, and elongation at 72°C for 30 s. A final elongation step was run at 72°C for 10 min. The PCR products were subjected to 2% agarose gel electrophoresis stained using ethidium bromide solution and visualized under trans-UV illumination.

Results {#sec1-3}
=======

This study was conducted on 100 *Salmonella enterica* strains which included *S*. Typhi (*n* =46), *S*. Paratyphi A (*n* = 12), and Group B *Salmonella* spp. (*n* = 42) recovered from blood culture samples between 2013 and 2017.

Among these isolates, 18 showed resistance to azithromycin by disc diffusion methodology with zones of inhibition \<13 mm. Of these 18 isolates, 10 were *S*. Typhi, three were *S*. Paratyphi A and five were Group B *Salmonella* spp. MICs of six of these isolates were ≥32 mg/L \[[Table 1](#T1){ref-type="table"}\].

###### 

Minimum inhibitory concentration values of Salmonella spp. showing azithromycin resistance by disc diffusion

  Identification      Disc diffusion^a^ (mm)   Disc diffusion^b^ (mm)   MIC (mg/Ll)
  ------------------- ------------------------ ------------------------ -------------
  *S.* Typhi          12                       12                       4
  *S.* Typhi          12                       11                       12
  *S.* Typhi          9                        8                        16
  *S.* Typhi          12                       12                       24
  *S.* Typhi          6                        6                        32
  *S.* Typhi          6                        6                        32
  *S.* Typhi          6                        6                        32
  *S.* Typhi          6                        6                        96
  *S.* Typhi          12                       11                       16
  *S.* Typhi          6                        6                        32
  *S.* Paratyphi A    6                        6                        8
  *S.* Paratyphi A    6                        8                        8
  *S.* Paratyphi A    10                       11                       24
  *S.* Paratyphi B    10                       11                       12
  *Salmonella* spp.   10                       12                       12
  *Salmonella* spp.   10                       12                       12
  *Salmonella* spp.   12                       12                       12
  *Salmonella* spp.   8                        10                       64

Disc diffusion^a^: HiMedia; Disc diffusion^b^: BD BBL Sensi disc. *S.* Typhi = *Salmonella* Typhi, *S.* Paratyphi = *Salmonella* Paratyphi, MIC = Minimum inhibitory concentration

MIC 50 and MIC 90 of azithromycin for *Salmonella* spp. was found to be 4 mg/L and 12 mg/L, respectively. Errors in susceptibility were evaluated when disc diffusion was compared with MIC values. Major error was seen in 12 isolates which were labeled as resistant by disc diffusion and showed MICs in the susceptible zone \[[Table 2](#T2){ref-type="table"}\].

###### 

Error classification of *Salmonella* spp. showing discordant results by disc diffusion and minimum inhibitory concentration

  Identification         Very major error   Major error   Minor error
  ---------------------- ------------------ ------------- -------------
  *S.* Typhi             0                  5             0
  *S.* Paratyphi A       0                  3             0
  *Salmonella* Group B   0                  1             0
  *Salmonella* species   0                  3             0
  Total                  0                  12            0

*S.* Typhi= *Salmonella* Typhi, *S.* Paratyphi = *Salmonella* Paratyphi

Synergy testing was inconclusive. MIC of azithromycin showed reduction when combined with ceftriaxone. However, the FIC indices did not show values supporting synergy \[[Supplemental Table 1](#ST1){ref-type="table"}\].

###### 

Synergy testing of Ceftriaxone and Azithromycin

  MIC~a~   MIC~b~   MIC~ab~   MIC~ba~   FIC Index
  -------- -------- --------- --------- -----------
  24       0.125    0.25      0.25      2.01
  32       0.125    0.25      0.25      2.007
  8        0.125    0.25      0.25      2.03
  16       0.047    0.125     0.125     2.607
  12       0.25     0.25      0.25      1.02
  4        0.125    0.125     0.125     1.02
  8        0.047    0.25      0.25      5.33
  32       0.125    0.25      0.25      2.007
  8        0.125    0.25      0.25      2.03
  32       0.125    0.25      0.25      2.007

MIC~a~: MIC of azithromycin; MIC~b~: MIC of ceftriaxone; MIC~ab~: MIC of the combination when ceftriaxone overlays azithromycin strip; MIC~ba~: MIC of the combination when azithromycin overlays ceftriaxone strip; FIC Index=MIC~ab~/MIC~a~+MIC~ba~/MIC~b~

Isolates which showed resistance by disc diffusion and MIC were investigated for *mphA* gene. A single isolate of Group B *Salmonella* spp. was positive for *mphA* gene. All the isolates were negative for *mphB* and *mef B* gene.

Mean MICs of azithromycin of the *Salmonella* spp. isolates from 2013 to 2017 were calculated and the mean MIC increased from 5 mg/L in 2013 to 24 mg/L in 2017. Azithromycin consumption as defined daily doses per 1000 patient days also showed an increase over the past 4 years \[[Figure 1](#F1){ref-type="fig"}\]. Mean MIC of ceftriaxone was also calculated and the ceftriaxone consumption was compared from 2013 to 2017. Mean MIC of ceftriaxone over the 4 years were around 0.13 mg/L. Ceftriaxone consumption also remained stable around 0.74 DDD/1000 patient days.

![Azithromycin consumption trends in the tertiary care hospital from 2013 to 2017 and mean minimum inhibitory concentration of *Salmonellae* spp. during that period](JLP-11-39-g001){#F1}

The clinical outcomes of the patients harboring six strains showing true resistance were analyzed. All the patients recovered with ceftriaxone treatment. Two patients received prolonged ceftriaxone therapy (14and 28 days). One patient gave a history of gall bladder polyps and repeated episodes of enteric fever \[[Table 3](#T3){ref-type="table"}\].

###### 

Clinical details of patients with azithromycin resistant salmonella infection

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Gender/age        Isolate from blood   Provisional diagnosis         Associated comorbidities               Clinical features                                                                   Ceftriaxone susceptibility   Ciprofloxacin susceptibility   Treatment                                             Outcome
  --------- ----------------- -------------------- ----------------------------- -------------------------------------- ----------------------------------------------------------------------------------- ---------------------------- ------------------------------ ----------------------------------------------------- -----------
  1         Female/18 years   *S.* Typhi           Enteric fever                 None                                   Low grade fever with mild chills, no rigor (1 weeks duration)\                      S                            R                              Ceftriaxone for 7 days, Cefixime for 7 days           Recovered
                                                                                                                        No history of abdominal pain, loose stools                                                                                                                                                            

  2         Male/57 years     *S.* Typhi           PUO                           HypertensionCoronary Artery Disease\   Low grade fever loss of appetite and weight loss\                                   S                            R                              Ceftriaxone 28 days\                                  Recovered
                                                                                 Mixed airway disease\                  Treated for enteric fever 1 week back                                                                                                           Azithromycin for 7 days                               
                                                                                 Gall Bladder polyp                                                                                                                                                                                                                           

  3         Male/55 years     *S.* Typhi           Enteric fever                 None                                   Low grade fever loss of appetite and weight loss stools; 2-3 episodes of vomiting   S                            R                              Ceftriaxone for 14 days                               Recovered

  4         Female/17 years   *S.* Typhi           PUO                           None                                   High grade fever for 10 days, nausea, vomiting loose stools                         S                            R                              Ceftriaxone for 14 days and Azithromycin for 5 days   Recovered

  5         Male/30 years     *S.* Typhi           Enteric fever                 None                                   Fever for 7 days with headache, 1 episode of vomiting                               S                            R                              Ceftriaxone for 14 days                               Recovered

  6         Female/70 years   Group B Salmonella   Retroperitoneal liposarcoma   Diabetes mellitus\                     Neuropathic pain                                                                    S                            S                              \-                                                    \-
                                                                                 Hypertension\                                                                                                                                                                                                                                
                                                                                 Splenectomy                                                                                                                                                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*S.* Typhi: *Salmonella* Typhi, *S.* Paratyphi = *Salmonella* Paratyphi

Discussion {#sec1-4}
==========

Enteric fever due to nalidixic acid resistant strains of typhoidal *Salmonellae* spp. requires ceftriaxone or azithromycin for its treatment.\[[@ref5][@ref13]\] While resistance to extended spectrum cephalosporins is uncommon, the need for parenteral therapy limits their use as a preferred first line treatment.\[[@ref14]\] Azithromycin appears to be an attractive oral alternative for treatment of uncomplicated enteric fever. However, as cautioned by Misra and Prasad, irrational antibiotic therapy and easy over the counter availability of azithromycin could contribute to its emerging resistance and subsequent treatment failure in *Salmonellae* spp.\[[@ref14]\]

Our study was conducted on 58 typhoidal *Salmonella* spp. and 42 nontyphoidal *Salmonella* spp. Among these isolates, 18% showed resistance to azithromycin if disc diffusion interpretive criteria were used to determine resistance. However, only 6% of the isolates showed true resistance as their MICs were ≥32 mg/L. An analysis of the discordant disc diffusion diameters showed that of the 12 isolates, eight (66.7%) had diameters between 10--12 mm. Of the 12 isolates showing discordant results between disc diffusion and MIC of azithromycin-five were *S*. Typhi, three *Salmonella* Paratyphi A and four *Salmonella* spp. As CLSI interpretive criteria were specific for *S*. Typhi, our study had extrapolated these criteria for *S*. Paratyphi A and *Salmonellae* spp. also. While this can be a major reason for the large number of discordant results, the presence of a considerable number of *S*. Typhi showing discordance is a matter of concern. Zone diameters of 10--12 mm can therefore be considered as grey areas for determining azithromycin resistance for *Salmonella* spp. Therefore, unlike other studies which found good correlation between disc diffusion diameters and MIC values, our study found disc diffusion diameters for determining azithromycin resistance as unreliable.\[[@ref14][@ref15]\] The results of this study indicate that isolates with diameters between 10--12 mm should be reconfirmed with respective MIC values before arriving at any conclusion.

Six isolates in this study showed true resistance to azithromycin. These isolates were studied for genes of azithromycin resistance - *mphA*, *mphB*, and *mefB*. The *mphA* gene was detected in a single isolate of non typhoidal *Salmonella* spp. Five *S*. Typhi isolates were negative for *mphA* gene while none of the isolates showed *mphB* and *mefB* genes. Azithromycin resistance in non typhoidal *Salmonellae* spp. has been reported from several centers.\[[@ref10][@ref16]\] Elevated MICs of typhoidal *Salmonella* spp. have been reported occasionally.\[[@ref17]\] The plasmid borne *mphA* gene has been reported as one of the reasons for azithromycin resistance.\[[@ref18]\] Association of a chromosomal macrolide inactivation gene cluster *mphA-mrx-mphr(A)* has also been associated with azithromycin resistance in non typhoidal *Salmonellae* spp.\[[@ref16]\] In the present study as well, a single high-level azithromycin-resistant isolate (MIC 64 mg/L) harbored the *mphA* gene, while other 5 (MIC: 16--32 mg/L) did not. These results indicate that the *mphA* gene may mediate a high level of resistance to azithromycin in *Salmonella*, as described previously in studies.\[[@ref10][@ref16]\] In addition, azithromycin resistance could arise from other probable mechanisms such as mutations in the *rlpV* and *rlpD* genes.\[[@ref19]\] Currently, few studies have investigated azithromycin resistance mechanisms in *Salmonella*, specifically, typhoidal salmonella.

Annual consumption of azithromycin in the hospital was tracked from 2014 to 2017. Azithromycin showed an increased consumption from 4.4DDD per 1000 patient days to 6.7 DDD per 1000 patient days. The mean MIC of *Salmonella* isolates also increased from 5 mg/L in 2013 to 24 mg/L in 2017 showing the MIC creep over 5 years. Therefore, the increasing utilization of this antibiotic probably had a considerable role to play in the development of resistance in these organisms. The easy over the counter availability of azithromycin and its widespread use for treating upper respiratory infections may have an important role to play in the emerging drug resistance among Salmonella species in our population. A comparison with the utilization of ceftriaxone in the hospital showed that the DDD s of ceftriaxone remained constant over the past 4 years. Therefore, our study reinforces that ceftriaxone can be used as an effective therapeutic option for culture proven enteric fever cases as well as empirical therapy for suspected cases of enteric fever.

The clinical outcome of six patients who harbored azithromycin resistant strains was analyzed. All patients were treated with injection ceftriaxone for 14 days. One patient showed gall bladder polyps and received an extended treatment with injection ceftriaxone for 28 days. All the patients growing typhoidal salmonella recovered with appropriate therapy. One patient received injection ceftriaxone and azithromycin in the initial course of therapy. Salmonella isolates with elevated azithromycin MICs have been isolated and reported from travellers from India and also from the Indian population. The clinical relevance of elevated MICs remains unknown. Clinically and microbiologically correlated breakpoints by Parry *et al*. indicates that azithromycin MIC of \<16 mg/L likely predicts a favorable clinical outcome.\[[@ref13]\] Azithromycin reaches 50--100 fold concentration within the macrophages and polymorphonuclear cells which is crucial in treating intracellular organisms of enteric fever; nevertheless, it achieves very low plasma levels. Hence, MIC might not be a good indicator of decreased susceptibility to azithromycin.\[[@ref20]\]

Conclusion {#sec1-5}
==========

This study has several limitations which include a small sample size, being a single center study, use of Estrip for MIC and use of interpretive criteria of *S*. Typhi for *S*. Paratyphi A and nontyphoidal salmonella. However, azithromycin disc diffusion diameter interpretations as recommended by CLSI can mislabel a few sensitive strains as resistant. Caution needs to be exercised when using disc diffusion breakpoints for *S*. Typhi to interpret nontyphoidal Salmonella breakpoints. *MphA* gene is seen in resistant nontyphoidal salmonella with high azithromycin MICs. It is not seen in isolates with lower MICs and in typhoidal *Salmonella*. While, further studies to understand the mechanism of resistance to azithromycin among Salmonella spp. is required, ceftriaxone continues to be a reliable drug for empirical treatment of enteric fever.
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